Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial

Juan Carlos Villar, Víctor Mauricio Herrera, Juan Guillermo Pérez Carreño, Eliana Váquiro Herrera, Yeny Zulay Castellanos Domínguez, Skarlet Marcell Vásquez, Zulma Milena Cucunubá, Nilda Graciela Prado, Yolanda Hernández, Juan Carlos Villar, Víctor Mauricio Herrera, Juan Guillermo Pérez Carreño, Eliana Váquiro Herrera, Yeny Zulay Castellanos Domínguez, Skarlet Marcell Vásquez, Zulma Milena Cucunubá, Nilda Graciela Prado, Yolanda Hernández

Abstract

Background: Either benznidazole (BZN) or nifurtimox (NFX) is recommended as equivalent to treat Trypanosoma cruzi infection. Nonetheless, supportive data from randomised trials is limited to individuals treated with BZN in southern cone countries of Latin America.

Methods: The goal of this randomised, concealed, blind, parallel-group trial is to inform the trypanocidal efficacy and safety of NFX and its equivalence to BZN among individuals with T. cruzi positive serology (TC+). Eligible individuals are TC+, 20-65 years old, with no apparent symptoms/signs or uncontrolled risk factors for cardiomyopathy and at negligible risk of re-infection. Consenting individuals (adherent to a 10-day placebo run-in phase) receive a 120-day BID blinded treatment with NFX, BZN or matching placebo (2:2:1 ratio). The four active medication arms include (1) a randomly allocated sequence of 60-day, conventional-dose (60CD) regimes (BZN 300 mg/day or NFX 480 mg/day, ratio 1:1), followed or preceded by a 60-day placebo treatment, or (2) 120-day half-dose (120HD) regimes (BZN 150 mg/day or NFX 240 mg/day, ratio 1:1). The primary efficacy outcome is the proportion of participants testing positive at least once for up to three polymerase chain reaction (PCR) assays (1 + PCR) 12-18 months after randomisation. A composite safety outcome includes moderate to severe adverse reactions, consistent blood marker abnormalities or treatment abandons. The trial outside Colombia (expected to recruit at least 60% of participants) is pragmatic; it may be open-label and not include all treatment groups, but it must adhere to the randomisation and data administration system and guarantee a blinded efficacy outcome evaluation. Our main comparisons include NFX groups with placebo (for superiority), NFX versus BZN groups and 60CD versus 120HD groups (for non-inferiority) and testing for the agent-dose and group-region interactions. Assuming a 1 + PCR ≥ 75% in the placebo group, up to 25% among BZN-treated and an absolute difference of up to ≥ 25% with NFX to claim its trypanocidal effect, 60-80 participants per group (at least 300 from Colombia) are needed to test our hypotheses (80-90% power; one-sided alpha level 1%).

Discussion: The EQUITY trial will inform the trypanocidal effect and equivalence of nitroderivative agents NFX and BZN, particularly outside southern cone countries. Its results may challenge current recommendations and inform choices for these agents.

Trial registration: ClinicalTrials.gov, NCT02369978 . Registered on 24 February 2015.

Keywords: Benznidazole; Chagas disese; Nifurtimox; Randomized controlled trial; Trypanosoma cruzi.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Process of treatment allocation
Fig. 2
Fig. 2
Daily 60-day treatment schedule for study participants

References

    1. World Health Organization. Chagas disease (American trypanosomiasis): epidemiology. WHO web site 2018. . Accessed 8 Oct 2018.
    1. Apt W, Heitmann I, Jercic MI, Jofré L, Muñoz P, Hauck IN, et al. Guía Clínica "Guías de Diagnóstico, Tratamiento y Prevención de la Enfermedad de Chagas". Santiago: Ministerio de Salud. Gobierno de Chile; 2018.
    1. Equipo de trabajo Convenio 637/09 deCooperación OPS/OMS-MPS . Guia de Atencion Clinica de la enfermedad de Chagas 2010. Bogotá: Ministerio de Salud y Protección Social, República de Colombia; 2010.
    1. Unidad deEpidemiología PNdC . Manual de Normas Técnicas y Operativas para el Tamizaje, Diagnóstico y Tratamiento de la Enfermedad de Chagas Crónica Reciente Infantil. La Paz: Ministerio de Salud y Deportes, Bolivia; 2007.
    1. Centers for Disease Control and Prevention. Parasites - American trypanosomiasis (also known as Chagas disease): antiparasitic treatment. CDC web site 2018 May 18. . Accessed 9 Oct 2018.
    1. Coura JR, Borges-Pereira J. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem Inst Oswaldo Cruz. 2011;106(6):641–645. doi: 10.1590/S0074-02762011000600001.
    1. Villar JC, Perez JG, Cortes OL, Riarte A, Pepper M, Marin-Neto JA, et al. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev. 2014;27(5):CD003463.
    1. de Andrade AL, Zicker F, de Oliveira RM, Almeida SS, Luquetti A, Travassos LR, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996;348(9039):1407–1413. doi: 10.1016/S0140-6736(96)04128-1.
    1. Sosa-Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg. 1998;59(4):526–529. doi: 10.4269/ajtmh.1998.59.526.
    1. Molina I, Prat J, Salvador F, Trevino B, Sulleiro E, Serre N, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med. 2014;370(20):1899–1908. doi: 10.1056/NEJMoa1313122.
    1. Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A, Jr, Rosas F, et al. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. N Engl J Med. 2015;373(14):1295–1306. doi: 10.1056/NEJMoa1507574.
    1. Morillo CA, Waskin H, Sosa-Estani S, Del Carmen BM, Cuneo C, Milesi R, et al. Benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: the STOP-CHAGAS trial. J Am Coll Cardiol. 2017;69(8):939–947. doi: 10.1016/j.jacc.2016.12.023.
    1. Torrico F, Gascon J, Ortiz L, Alonso-Vega C, Pinazo MJ, Schijman A, et al. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infect Dis. 2018;18(4):419–430. doi: 10.1016/S1473-3099(17)30538-8.
    1. Coura JR, de Abreu LL, Willcox HP, Petana W. Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation. Rev Soc Bras Med Trop. 1997;30(2):139–144. doi: 10.1590/S0037-86821997000200009.
    1. Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLOS Negl Trop Dis. 2009;3(7):e488. doi: 10.1371/journal.pntd.0000488.
    1. Schijman AG, Bisio M, Orellana L, Sued M, Duffy T, Mejia Jaramillo AM, et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLOS Negl Trop Dis. 2011;5(1):e931. doi: 10.1371/journal.pntd.0000931.
    1. Ramirez JC, Cura CI, da Cruz MO, Lages-Silva E, Juiz N, Velazquez E, et al. Analytical validation of quantitative real-time PCR methods for quantification of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. J Mol Diagn. 2015;17(5):605–615. doi: 10.1016/j.jmoldx.2015.04.010.
    1. Villar JC. Commentary: Control of Chagas' disease: let's put people before vectors. Int J Epidemiol. 2001;30(4):894–895. doi: 10.1093/ije/30.4.894.
    1. Bello CR, Aceijas C, Alves PAB, Garelick H. Evolution of Chagas' disease in Brazil. Epidemiological perspective and challenges for the future: a critical review. Perspect Public Health. 2017;137(5):289–295. doi: 10.1177/1757913916671160.
    1. Yamey G, Hotez P. Neglected tropical diseases. BMJ. 2007;335(7614):269–270. doi: 10.1136/bmj.39281.645035.80.
    1. Altcheh J, Moscatelli G, Mastrantonio G, Moroni S, Giglio N, Marson ME, et al. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. PLOS Negl Trop Dis. 2014;8(5):e2907. doi: 10.1371/journal.pntd.0002907.
    1. Pinazo MJ, Guerrero L, Posada E, Rodriguez E, Soy D, Gascon J. Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic Chagas disease. Antimicrob Agents Chemother. 2013;57(1):390–395. doi: 10.1128/AAC.01401-12.
    1. Cancado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo. 2002;44(1):29–37. doi: 10.1590/S0036-46652002000100006.
    1. Alvarez MG, Hernandez Y, Bertocchi G, Fernandez M, Lococo B, Ramirez JC, et al. New scheme of intermittent benznidazole administration in patients chronically infected with Trypanosoma cruzi: a pilot short-term follow-up study with adult patients. Antimicrob Agents Chemother. 2016;60(2):833–837. doi: 10.1128/AAC.00745-15.
    1. Olivera MJ, Fory JA, Olivera AJ. Therapeutic drug monitoring of benznidazole and nifurtimox: a systematic review and quality assessment of published clinical practice guidelines. Rev Soc Bras Med Trop. 2017;50(6):748–755. doi: 10.1590/0037-8682-0399-2016.
    1. Bianchi F, Cucunuba Z, Guhl F, Gonzalez NL, Freilij H, Nicholls RS, et al. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia. PLOS Negl Trop Dis. 2015;9(2):e0003465. doi: 10.1371/journal.pntd.0003465.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit